{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Boele FW"],"funding":["European Organisation for Research and Treatment of Cancer"],"pagination":["2959-2974"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12908480"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(11)"],"pubmed_abstract":["Background
Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.Methods
In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor l"],"journal":["Neuro-oncology"],"pubmed_title":["Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation."],"pmcid":["PMC12908480"],"funding_grant_id":["004-2018"],"pubmed_authors":["Welsh L","Weller M","Dehais C","Ryden I","Jena R","Noel G","Muhic A","Ashkan K","Vauleon E","Hertler C","Ducray F","Desideri I","Mehta S","Burger MC","Boele FW","Haldbo-Classen L","Sanghera P","Darlix A","Tabouret E","Frances SM","Hrab I","Dahlrot RH","Herrlinger U","Klein M","Kazda T","Malmstrom A","Durando X","Cartalat S","Lawson McLean A","McBain C","Guerdoux E","Razis E","Bourg V","Renovanz M","Foweraker K","Werner JM","Engelhardt J","Lord H"],"additional_accession":[]},"is_claimable":false,"name":"Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation.","description":"Background
Patients with oligodendroglioma have a relatively favorable prognosis. The long-term impacts of the tumor itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.Methods
In this cross-sectional observational study, patients with oligodendroglioma, isocitrate dehydrogenase-mutant and 1p/19q-codeleted, diagnosed ≥ 5 years ago, were recruited. Patients completed patient-reported outcome measures (EORTC QLQ-C30; BN20; MOS Cognitive Complaints Scale) and cognitive tests (HVLT-R, TMT, COWAT). Associations between HRQOL and cognition outcomes, and clinical variables (time since diagnosis; age at diagnosis; progression; tumor l","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Nov","modification":"2026-07-16T05:05:25.254Z","creation":"2026-07-09T10:38:07.178Z"},"accession":"S-EPMC12908480","cross_references":{"pubmed":["40692477"],"doi":["10.1093/neuonc/noaf172"]}}